August 15, 2016

Karos Pharmaceuticals Announces Major Milestone Events

New Haven, CT, USA.  Karos Pharmaceuticals, Inc., a privately held biopharmaceutical company developing therapeutic agents to modulate peripheral serotonin synthesis to treat orphan indications, including pulmonary arterial hypertension (PAH) and carcinoid syndrome, announces several major achievements, including the success of the Phase 1 clinical trials of KAR5585, the closing of the Series B round of financing, US issuance of a composition of matter patent for KAR5585, and the appointment of Ed Mascioli, MD, as Chief Executive Officer. [More]


April 13, 2016

Karos Pharmaceuticals Advances Development of KAR5585 to Treat Pulmonary Arterial Hypertension into the Clinic
First-in-class small molecule candidate designed to alter course of disease through selective modulation of peripheral serotonin

NEW HAVEN, Conn.–(BUSINESS WIRE)–Karos Pharmaceuticals, a privately held, clinical-stage biopharmaceutical company focused on orphan indications, including fibrotic, inflammatory, and metabolic diseases, today announced that the Company has advanced its small molecule drug candidate, KAR5585, into the clinic. KAR5585 is being developed for the treatment of pulmonary arterial hypertension (PAH) and other rare diseases marked by extensive fibrosis. KAR5585 is a first-in-class, selective inhibitor of tryptophan hydroxylase 1 (TPH1) designed to reduce peripheral serotonin (5-HT) and 5-HT-associated vascular remodeling and fibrosis that are the hallmarks of PAH. Karos has completed the single ascending dose portion of its 120-patient Phase 1 clinical trial in healthy volunteers and is now conducting the multiple ascending dose portion of the study, with the goal of reporting results from the Phase 1 program in the middle of this year.  [More]